Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

21. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9)

, in Adults With Type 2 Diabetes (Onset 9) , , , , , , , , , , Affiliations Expand Affiliations 1 Mountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com. 2 Novo Nordisk A/S, Søborg, Denmark. 3 Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea. 4 Novo Nordisk A/S, Aalborg, Denmark. 5 Santojanni Hospital and CENUDIAB, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina. 6 Institute (...) Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (Onset 9) Wendy S Lane et al. Diabetes Care . 2020 . Show details Diabetes Care Actions . 2020 Mar 24;dc192232. doi: 10.2337/dc19-2232. Online ahead of print. Authors , , , , , , , , , , Affiliations 1 Mountain Diabetes and Endocrine Centre, Asheville, NC mountaindiabetes@msn.com. 2 Novo Nordisk A/S

2020 EvidenceUpdates

22. Metabolic surgery for the treatment of type 2 diabetes: A network meta-analysis of randomized controlled trials Full Text available with Trip Pro

Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14045. Online ahead of print. Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials , , , Affiliations Expand Affiliations 1 Diabetology, Careggi Hospital, Florence, Italy. 2 University of Florence, Florence, Italy. PMID: 32243058 DOI: Item in Clipboard Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Meta-Analysis of Randomized Controlled Trials Barbara Cresci et al (...) . Diabetes Obes Metab . 2020 . Show details Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14045. Online ahead of print. Authors , , , Affiliations 1 Diabetology, Careggi Hospital, Florence, Italy. 2 University of Florence, Florence, Italy. PMID: 32243058 DOI: Item in Clipboard Full-text links Cite Abstract Aim: To compare different types of metabolic surgery (MS) with medical therapy (MT) for the treatment of type 2 diabetes (T2D). Materials and methods: We conducted a network-meta-analysis

2020 EvidenceUpdates

23. Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial Full Text available with Trip Pro

: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial , , , , , , , , , Affiliations Expand Affiliations 1 Diabetes Centre, Institute for Clinical (...) School, Perugia, Italy. PMID: 32243043 DOI: Item in Clipboard Differential Glycaemic Control With Basal Insulin Glargine 300 U/mL Versus Degludec 100 U/mL According to Kidney Function in Type 2 Diabetes: A Subanalysis From the BRIGHT Trial Martin Haluzík et al. Diabetes Obes Metab . 2020 . Show details Diabetes Obes Metab Actions . 2020 Apr 3. doi: 10.1111/dom.14043. Online ahead of print. Authors , , , , , , , , , Affiliations 1 Diabetes Centre, Institute for Clinical and Experimental Medicine

2020 EvidenceUpdates

24. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial

Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial (...) : ( ) Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Apr 15;dc192452. doi: 10.2337/dc19-2452. Online ahead of print. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2

2020 EvidenceUpdates

25. Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Full Text available with Trip Pro

Combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in people with type 1 diabetes: A randomized crossover trial Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial - PubMed This site needs JavaScript to work properly. Please enable it to take (...) when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2020 Mar 12. doi: 10.1111/dom.14028. Online ahead of print. Combined Continuous Glucose Monitoring and Subcutaneous Insulin Infusion Versus Self-Monitoring of Blood Glucose With Optimized Multiple Injections in People With Type 1 Diabetes: A Randomized Crossover Trial

2020 EvidenceUpdates

26. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. (Abstract)

Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. The restricted mean survival time (RMST) has been advocated as an alternative or a supplement to the hazard ratio for reporting the effect of an intervention in a randomized clinical trial. The RMST difference allows quantification of the postponement of an outcome during a specified (restricted) interval and corresponds to the difference between (...) the areas under the 2 survival curves for the intervention and control groups. This article presents examples of the use of the RMST in a research and a clinical context. First, the authors demonstrate how the RMST difference can answer research questions about the efficacy of different treatments. Estimates are presented for the effects of pharmacologic or strategy-driven glucose-lowering interventions for adults with type 2 diabetes from 36 trials and 9 follow-up studies reporting cardiovascular

2020 Annals of Internal Medicine

27. Insulin pumps for people with Type 1 Diabetes

Insulin pumps for people with Type 1 Diabetes 1 Driving better decision-making in healthcare Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes Technology Guidance from the MOH Medical Technology Advisory Committee Published on 23 March 2020 Guidance recommendations The Ministry of Health Medical Technology Advisory Committee has recommended: ? Continuous subcutaneous insulin infusion therapy (CSII) and its consumables as a treatment option for adults and children (...) with type 1 diabetes mellitus: o who use multiple daily injections of insulin (MDI) to achieve target HbA1c but result in the person experiencing disabling hypoglycaemia, where disabling hypoglycaemia is defined as the repeated and unpredictable occurrence of hypoglycaemia that results in persistent anxiety about recurrence and is associated with a significant adverse effect on quality of life (QoL); or o who have unacceptably high HbA1c (i.e. at 8.5% or above) on MDI despite a high level of care, where

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

28. Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus

Insulin glargine/lixisenatide (Suliqua) - for the treatment of adults with type 2 diabetes mellitus 1 Published 13 April 2020 1 SMC2235 insulin glargine plus lixisenatide (Suliqua®), 100 units/mL plus 50 microgram/mL and 100 units/mL plus 33 micrograms/mL solution for subcutaneous injection in pre-filled pens Aventis Pharma Limited, trading as Sanofi 06 March 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug (...) insulin. SMC restriction: for use in patients who are uncontrolled on basal insulin (glycosylated haemoglobin [HbA1c] > 7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin analogues. Insulin glargine/lixisenatide improved glycaemic control compared with insulin glargine alone in adults with inadequately controlled type 2 diabetes mellitus. Chairman Scottish Medicines Consortium www.scottishmedicines.org.uk 2 Indication

2020 Scottish Medicines Consortium

29. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis Full Text available with Trip Pro

Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) : Send at most: Send even when there aren't any new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions . 2020 Mar 4;dc191162. doi: 10.2337/dc19-1162. Online ahead of print. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis

2020 EvidenceUpdates

30. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. (Abstract)

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest (...) favorable effects on clinical outcomes.To test whether apabetalone significantly reduces major adverse cardiovascular events.A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.Patients were

2020 JAMA

31. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk Full Text available with Trip Pro

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk To investigate the effects of semaglutide versus comparators on major adverse cardiovascular events (MACE: cardiovascular [CV] death, nonfatal myocardial infarction [MI] and nonfatal stroke) and hospitalization for heart failure (HF) in the SUSTAIN (subcutaneous semaglutide) and PIONEER (oral semaglutide) trials across subgroups of varying CV risk.Post hoc analyses of individual (...) stroke (HR 0.65 [95% CI 0.43, 0.97]). The HR for hospitalization for HF was 1.03 (95% CI 0.75, 1.40). The HRs for MACE were <1.0 in all subgroups, except for those with prior HF (HR 1.06 [95% CI 0.72, 1.57]); P-values for interaction of subgroup on treatment effect were >0.05, except for HF (0.046). In the combined glycaemic efficacy trials, the HR for effect of semaglutide versus comparators on MACE was 0.85 (95% CI 0.55, 1.33).In SUSTAIN and PIONEER combined, glucagon-like peptide-1 analogue

2020 EvidenceUpdates

32. Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study Full Text available with Trip Pro

Human regular U-500 insulin via continuous subcutaneous insulin infusion versus multiple daily injections in adults with type 2 diabetes: The VIVID study To compare the safety and efficacy of U500-R delivered by a novel, specifically designed U500-R insulin pump with U-500R delivered by multiple daily injections (MDI).The phase 3 VIVID study randomized people with type 2 diabetes to U-500R by continuous subcutaneous insulin infusion (CSII) or MDI. Participants (aged 18-85 years) had HbA1c ≥7.5 (...) <0.001); fasting plasma glucose, -33.9 mg/dL (-1.9 mmol/L) with CSII and 1.7 mg/dL (0.09 mmol/L) with MDI (difference - 35.6 mg/dL [-2.0 mmol/L], P <0.001); total daily dose, 2.8 U with CSII and 51.3 U with MDI (P < 0.001). Weight changes and rates of documented symptomatic and severe hypoglycaemia were similar between groups; the CSII group had a higher rate of nocturnal hypoglycaemia.In type 2 diabetes requiring high doses of insulin, both methods of U-500R delivery lowered HbA1c. However, the CSII

2020 EvidenceUpdates

33. Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan (Abstract)

(nonexposure group), aged 20-79 years, were included between 1 April 2006 and 31 May 2015. Patients with a history of diabetes mellitus or receipt of antidiabetes treatment were excluded. Covariates were adjusted by using propensity score matching; the associations were analyzed between risk of new-onset type 2 diabetes and the duration of antidepressant use/dose of antidepressant in the exposure and nonexposure groups by using Cox proportional hazards models. Changes in glycated hemoglobin (HbA1c) level (...) Association Between the Use of Antidepressants and the Risk of Type 2 Diabetes Mellitus: A Large, Population-Based Cohort Study in Japan This study aimed to reveal the associations between the risk of new-onset type 2 diabetes mellitus and the duration of antidepressant use and the antidepressant dose, and between antidepressant use after diabetes onset and clinical outcomes.In this large-scale retrospective cohort study in Japan, new users of antidepressants (exposure group) and nonusers

2020 EvidenceUpdates

34. A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice Full Text available with Trip Pro

) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs) were randomized 1:1 to open-label IDegLira or IGlar U100. Visits were scheduled at weeks 1, 2, 4 and 12, and every 3 months thereafter. After 26 weeks, glycated haemoglobin (HbA1c) reductions were greater with IDegLira versus IGlar U100 (-21.5 vs. -16.4 mmol/mol [-2.0 vs. -1.5%]), as was the percentage of participants achieving HbA1c <53 mmol/mol (78.7% vs. 55.7%) and HbA1c targets without weight gain and/or hypoglycaemia (...) A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants (N = 1012

2020 EvidenceUpdates

35. Efficacy of 10-20-30 training versus moderate-intensity continuous training on HbA1c, body composition and maximum oxygen uptake in male patients with type 2 diabetes: A randomized controlled trial (Abstract)

Efficacy of 10-20-30 training versus moderate-intensity continuous training on HbA1c, body composition and maximum oxygen uptake in male patients with type 2 diabetes: A randomized controlled trial To compare the efficacy of 10-20-30 training versus moderate-intensity continuous training (MICT) on HbA1c, body composition and maximum oxygen uptake (V˙O2 max) in male patients with type 2 diabetes (T2D).Fifty-one male participants with T2D were randomly assigned (1:1) to a 10-20-30 (N = 26

2020 EvidenceUpdates

36. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. (Abstract)

Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Hyperuricemia is common in patients with type 2 diabetes mellitus and is known to cause gout. Sodium-glucose cotransporter-2 (SGLT2) inhibitors prevent glucose reabsorption and lower serum uric acid levels.To compare the rate of gout between adults prescribed an SGLT2 inhibitor and those prescribed a glucagon-like peptide-1 (GLP1) receptor (...) agonist.Population-based new-user cohort study.A U.S. nationwide commercial insurance database from March 2013 to December 2017.Persons with type 2 diabetes newly prescribed an SGLT2 inhibitor were 1:1 propensity score matched to patients newly prescribed a GLP1 agonist. Persons were excluded if they had a history of gout or had received gout-specific treatment previously.The primary outcome was a new diagnosis of gout. Cox proportional hazards regression was used to estimate hazard ratios (HRs) of the primary

2020 Annals of Internal Medicine

37. Sotagliflozin with insulin for treating type 1 diabetes

Sotagliflozin with insulin for treating type 1 diabetes Sotagliflozin with insulin for treating type 1 diabetes T echnology appraisal guidance Published: 12 February 2020 www.nice.org.uk/guidance/ta622 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available (...) an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sotagliflozin with insulin for treating type 1 diabetes (TA622) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 21Contents Contents 1 Recommendations 4 2 Information about sotagliflozin 6 3 Committee discussion 7 Clinical management 7 Experience of people

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

38. Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY

Comprehensive Type 2 Diabetes Management Algorithm - EXECUTIVE SUMMARY Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY | American Association of Clinical Endocrinologists search Search Resources BACK Offering Guidance Through the Latest Science on Bone-Related Disorders Treat your diabetes patients with expert precision. Offering Guidance Through the Latest Science on Lipid Conditions Education Menu FEATURED EMBR AACE 2020 EMBR AACE , the AACE 29 th Annual (...) to enhancing our members’ knowledge, education, and practice management skills so they can focus on providing the highest quality of patient care. We also advocate for the profession to create understanding of the value of our community to patients, organizations and the public. search Breadcrumb Comprehensive Type 2 Diabetes Management Algorithm (2020) - EXECUTIVE SUMMARY Footer Navigation Partner With Us Join us to develop an open dialogue between industry and foster AACE in the furtherance of patient

2020 American Association of Clinical Endocrinologists

39. Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes (Abstract)

Performance of the ESC 0/1-h and 0/3-h Algorithm for the Rapid Identification of Myocardial Infarction Without ST-Elevation in Patients With Diabetes Patients with diabetes mellitus (DM) have elevated levels of high-sensitivity cardiac troponin (hs-cTn). We investigated the diagnostic performance of the European Society of Cardiology (ESC) algorithms to rule out or rule in acute myocardial infarction (AMI) without ST-elevation in patients with DM.We prospectively enrolled 3,681 patients (...) with suspected AMI and stratified those by the presence of DM. The ESC 0/1-h and 0/3-h algorithms were used to calculate negative and positive predictive values (NPV, PPV). In addition, alternative cutoffs were calculated and externally validated in 2,895 patients.In total, 563 patients (15.3%) had DM, and 137 (24.3%) of these had AMI. When the ESC 0/1-h algorithm was used, the NPV was comparable in patients with and without DM (absolute difference [AD] -1.50 [95% CI -5.95, 2.96]). In contrast, the ESC 0/3-h

2020 EvidenceUpdates

40. Management of Type 2 Diabetes Mellitus

complications. Key points Prevention. In individuals at risk for type 2 diabetes (see Table 1), type 2 diabetes can be delayed or prevented through diet, exercise, and pharmacologic interventions [IA]. Screening. Although little evidence is available on screening for diabetes, screening should be considered every 3 years beginning at age 45 or annually at any age if BMI = 25 kg/m 2 [evidence: IID], history of hypertension [IIB], gestational diabetes [IC], or other risk factors. Diagnosis. An A1c of 6.5 (...) = generally should not be performed. Level of evidence supporting a diagnostic method or an intervention: A=randomized controlled trials; B=controlled trials, no randomization; C=observational trials; D=opinion of expert panel. 2 UMHS Management of Type 2 Diabetes Mellitus June, 2017 Table 1. Diagnosis of Diabetes: Diagnostic Tests and Glucose Values Diagnostic Test Normal Pre-diabetes Diabetes Hemoglobin A1c (A1c) a 30 mg/gm, check UA to rule out asymptomatic UTI. • Repeat spot urine ratio twice within 6

2020 University of Michigan Health System